RBC Capital Initiates Coverage On Pyxis Oncology with Outperform Rating, Announces Price Target of $7
Portfolio Pulse from Benzinga Newsdesk
RBC Capital analyst Leonid Timashev has initiated coverage on Pyxis Oncology (NASDAQ:PYXS) with an Outperform rating and a price target of $7.
September 05, 2023 | 11:04 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
RBC Capital has initiated coverage on Pyxis Oncology with an Outperform rating and a price target of $7, which could positively impact the stock's performance.
Analyst ratings and price targets can significantly influence a stock's performance. In this case, RBC Capital's Outperform rating suggests that they expect Pyxis Oncology to outperform the market or its sector in the near term. Additionally, the price target of $7 indicates their expectation of the stock's potential upside. This could lead to increased investor interest and a potential rise in the stock's price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100